ExAdEx-Innov is proud to contribute to a new collaborative study published in Scientific Reports, a journal of Nature group, “First comparison of commercial systems to prepare nanofat: technical performances and biological quality differ among obtained products”. The publication aligns closely with our core expertise in human adipose tissue, adipose tissue quality assessment, and the evaluation of processing technologies for regenerative applications.
As experts in adipose tissue, we know that the way fat is processed can have a major impact on the quality and biological properties of the final product.
Nanofat is increasingly used in regenerative and aesthetic medicine and tissue repair, but its preparation remains highly variable across devices. This variability can influence cell composition, extracellular matrix content, inflammation and preservation of tissue structures and native vascularization, making robust evaluation methods essential. The study addresses this need by combining technical readouts with biological characterization, offering a more complete view of device performance.
The study shows that device performance cannot be judged by ease of use alone. Biological quality, cellular composition, and preservation of adipose structures also need to be considered. The results showed that while all devices performed satisfactorily from a technical standpoint, their biological outputs differed substantially.
For ExAdEx-Innov, this publication illustrates the importance of connecting adipose tissue expertise with device evaluation and tissue quality analysis. Our approach is built to provide deeper insight into the behavior of human adipose tissue, helping to distinguish simple processing convenience from true biological relevance.
This kind of work supports our broader mission: advancing innovative solutions for pharmaceutical, dermo-cosmetic, nutraceutical, aesthetic, and reconstructive applications through a better understanding of human adipose tissue. It also reinforces the need for standardized methods and qualification criteria when working with fat-derived materials intended for regenerative use.
https://www.nature.com/articles/s41598-026-40847-2
Follow us on LinkedIn and contact us for more information.
ExAdEx-Innov proudly contributed to the 19th International Symposium “Cosmetic Science: Shaping the Future” organized by the Société Française de Cosmétologie (SFC) in Paris on December
EXADEX-INNOV is excited to announce that Resalis Therapeutics will present preclinical translational data at Obesity Week 2025, including results obtained on our human adipose tissue
Our journey as part of the French biotech delegation during the Nordic Biotech Mission, organized by Business France Nordics and Bpifrance in Sweden and Denmark,
Copyright © 2022 ExAdEx-Innov All rights reserved
KOL on adipose tissue biology.
Research Director (DR1 INSERM).
Team Leader of « Stem Cells and Differentiation » Lab at Institut de Biologie Valrose (Nice).
Label of Laboratoire d’Excellence by the French National Research Agency (Investissements pour le Futur, Labex Signalife program).
Co-inventor of 5 patents
Expert in clinical applications of adipose tissue.
Plastic Reconstructive and Aesthetic Surgeon in Nice.
Member of the Medical Council of Alpes Maritimes region.
Expert for the French National Regulatory Agency ANSM for medical devices.
Certified by French Health Autority HAS (2020-2024).
PhD thesis (2018) on fat tissue and adipose tissue stem cells grafting.
Expert in cell therapy and immunology.
Senior Lecturer (Maitre de conférences).
Responsible of the Cell and Gene Therapy Unity of Nice University Hospital (CHU de Nice).
Director of « Micoralis » research team at Université Côte d’Azur (Nice).
Founder and CEO of the biotech company Biointerférence (2003-2006).
Co-inventor of 5 patents.
Vincent is responsible of company strategy and technological innovation, thanks to his double skill set in science and deeptech startup development.
With a deep knowledge and vision about ExAdEx technology, Vincent has actively worked as a deeptech entrepreneur to push further the development of breakthrough innovative products around human adipose tissue, which lead him to create ExAdEx-Inov.
In addition to his entrepreneurial skills, Vincent has a strong background in biology (PhD in Cellular and Molecular Biology from Université Côte d’Azur) and training in clinical research management (CRA training at the Faculty of Medicine of La Timone, Marseille).
He is co-inventor of the 2 company’s patent families.
Main areas of expertise: DeepTech entrepreneur; Bioengineering of human adipose tissue.
Luigi is responsible of the management of company operations and business development strategy, thanks to his expertise in biotech startup development.
With a double competence and training in business and science (including an MBA from IAE Paris Sorbonne Business School and a PhD in Cytological Sciences from Rome University La Sapienza), Luigi has been managing business development and R&D projects in a preclinical CRO and a biotech startup company in previous years.
He has been supporting ExAdEx-Innov project and business development since his position as an Entrepreneur in Residence for CNRS Innovation Tech Transfer Office in 2021.
Main areas of expertise: Biotech Startup Business Development; Project management
